Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
VTVT logo VTVT
Upturn stock ratingUpturn stock rating
VTVT logo

vTv Therapeutics Inc (VTVT)

Upturn stock ratingUpturn stock rating
$15.3
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: VTVT (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $35.5

1 Year Target Price $35.5

Analysts Price Target For last 52 week
$35.5 Target price
52w Low $12.62
Current$15.3
52w High $26.99

Analysis of Past Performance

Type Stock
Historic Profit -45.98%
Avg. Invested days 21
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 40.04M USD
Price to earnings Ratio -
1Y Target Price 35.5
Price to earnings Ratio -
1Y Target Price 35.5
Volume (30-day avg) 2
Beta 0.57
52 Weeks Range 12.62 - 26.99
Updated Date 08/15/2025
52 Weeks Range 12.62 - 26.99
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.92

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -150717.64%

Management Effectiveness

Return on Assets (TTM) -43.93%
Return on Equity (TTM) -209.04%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 14200389
Price to Sales(TTM) 2355.5
Enterprise Value 14200389
Price to Sales(TTM) 2355.5
Enterprise Value to Revenue 835.32
Enterprise Value to EBITDA -2.11
Shares Outstanding 2617220
Shares Floating 2222016
Shares Outstanding 2617220
Shares Floating 2222016
Percent Insiders 35.6
Percent Institutions 22.11

ai summary icon Upturn AI SWOT

vTv Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing orally administered small molecule drug candidates to treat a range of human diseases. Founded in 2015, the company focuses on diseases where unmet medical needs are high.

business area logo Core Business Areas

  • Pharmaceutical Development: Focuses on the research, development, and potential commercialization of novel therapeutics.

leadership logo Leadership and Structure

Details on leadership team and organizational structure are not readily available in detail.

Top Products and Market Share

overview logo Key Offerings

  • TTP399: An oral small molecule designed to activate glucokinase in the liver and pancreas. Clinical trials are ongoing for Type 1 diabetes (T1D). Market share data is not available as it is in clinical trials. Competitors include companies developing novel diabetes therapies, such as Novo Nordisk (NVO), Eli Lilly (LLY), and Sanofi (SNY).

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is highly competitive, with companies vying to develop innovative treatments for various diseases. It is heavily regulated and requires substantial investment in research and development.

Positioning

vTv Therapeutics Inc. is a small, clinical-stage company with a focus on diabetes. It aims to differentiate itself through its novel glucokinase activator, TTP399.

Total Addressable Market (TAM)

The global diabetes market is substantial, projected to reach hundreds of billions of dollars. vTv Therapeutics is positioned to capture a share of this market if TTP399 proves successful in clinical trials.

Upturn SWOT Analysis

Strengths

  • Novel glucokinase activator (TTP399)
  • Focus on unmet needs in diabetes
  • Experienced management team

Weaknesses

  • Reliance on a single key drug candidate (TTP399)
  • Limited financial resources
  • High risk of clinical trial failure

Opportunities

  • Positive clinical trial results for TTP399
  • Partnerships with larger pharmaceutical companies
  • Expansion into other therapeutic areas

Threats

  • Clinical trial failures
  • Competition from established diabetes therapies
  • Regulatory hurdles
  • Inability to raise additional capital

Competitors and Market Share

competitor logo Key Competitors

  • NVO
  • LLY
  • SNY

Competitive Landscape

vTv Therapeutics Inc. is a small player compared to established pharmaceutical giants. Its success hinges on the unique value proposition of TTP399.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is largely dependent on clinical trial progress and investor sentiment.

Future Projections: Future growth is highly dependent on the success of TTP399 in clinical trials. Analyst estimates will be highly variable.

Recent Initiatives: Recent initiatives likely revolve around advancing TTP399 through clinical trials and seeking partnerships.

Summary

vTv Therapeutics is a high-risk, high-reward clinical-stage biotech focused on developing TTP399 for diabetes. Its success depends on positive clinical trial results and securing funding or partnerships. The company faces significant competition from established pharmaceutical companies and is susceptible to regulatory and financial risks.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Industry reports
  • Market data providers

Disclaimers:

This analysis is based on available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share data is estimated and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About vTv Therapeutics Inc

Exchange NASDAQ
Headquaters High Point, NC, United States
IPO Launch date 2015-07-30
CEO, President & Chairman of the Board Mr. Paul J. Sekhri M.Sc.
Sector Healthcare
Industry Biotechnology
Full time employees 23
Full time employees 23

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of postprandial hyperglycemia in cystic fibrosis related diabetes patients, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non- central nervous system penetrant PDE4 inhibitor that has completed Phase 1 trials for the treatment of inflammatory diseases. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2"related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress. It has a license agreement Newsoara Biopharma Co., Ltd. o develop and commercialize phosphodiesterase type 4 inhibitors program, including the compound HPP737. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Group LLC.